Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29 | Direct | 32,000 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193125-26-294703 · ownership.xml · derivative · entry 1 Banks Sonja · CIK 0001896415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-29 F1 · derivative.exercise_date: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000950170-25-091579 · ownership.xml · derivative · entry 1 Banks Sonja · CIK 0001896415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2035-06-25 F1 · derivative.exercise_date: This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074882 · ownership.xml · derivative · entry 1 Banks Sonja · CIK 0001896415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0000950170-23-030758 · ownership.xml · derivative · entry 1 Banks Sonja · CIK 0001896415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:00 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000899243-22-024523 · doc4.xml · derivative · entry 1 Banks Sonja · CIK 0001896415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 21:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $15.73 | $0.00 |
DisclosureSEC source: 0000899243-21-047542 · doc4.xml · derivative · entry 1 Banks Sonja · CIK 0001896415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: This option was granted on December 8, 2021 and is scheduled to vest in equal monthly installments until December 8, 2024, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.